Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis
Open Access
- 1 November 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 26 (5) , 1123-1130
- https://doi.org/10.1002/hep.510260506
Abstract
Antinuclear antibodies (ANA) staining nuclear dot structures predominantly occur in primary biliary cirrhosis (PBC) patients and recognize the Sp100 and promyelocytic leukemia protein (PML). From retrospective analysis of sera from a clinically well-defined Canadian series of 170 PBC patients included into a 24-month therapeutic trial of ursodeoxycholic acid (UDCA), we report the prevalence of these ANA and their dynamics in the course of the disease. Using an enzyme-linked immunosorbent assay (ELISA), anti-Sp100 autoantibodies were shown in 35 (21%) patients. Thirty-three patients (19%) had autoantibodies against PML as determined by indirect immunostaining of cells overexpressing PML. Altogether, anti-nuclear dot autoantibodies were present in 25% of the 170 PBC patients. Their occurrence correlated with an unfavorable disease course, because these patients progressed significantly more frequently from early stages (I/II) to late stages (III/IV) within the 24-month observation period (P < .05). During the course of the disease, the autoantibody levels against the Sp100 full-length protein remained nearly constant in all 35 positive patients. However, 9 patients showed remarkable changes in Sp100 epitope recognition as revealed by ELISA and immunoblotting. When the occurrence of these changes and the treatment of the patients were compared retrospectively, it became evident that 8 of the 9 patients had received UDCA (42% of all Sp100-positive patients treated with UDCA). These findings indicate subtle changes of the Sp100 epitope recognition pattern during the natural course of the disease and its induction or acceleration by UDCA treatment. This implies that UDCA can modulate immunoglobulin (Ig) expression not only quantitatively, but also qualitatively.Keywords
This publication has 43 references indexed in Scilit:
- Interferon‐Modulated Expression of Genes Encoding the Nuclear‐Dot‐Associated Proteins Sp100 and Promyelocytic Leukemia Protein (PML)European Journal of Biochemistry, 1996
- Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosisHepatology, 1996
- Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosisGastroenterology, 1996
- Two Nuclear Dot‐Associated Proteins, PML and SplOO, are Often Co‐Autoimmunogenic in Patients with Primary Biliary CirrhosisScandinavian Journal of Immunology, 1995
- Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cellsCell, 1994
- Differential Effects of Chenodeoxycholic and Ursodeoxycholic Acids on Interleukin 1, Interleukin 6 and Tumor Necrosis Factor-α Production by MonocytesHepatology, 1992
- Immunomodulatory Effects of Ursodeoxycholic Acid on Immune ResponsesHepatology, 1992
- The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locusNature, 1990
- Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis.The Journal of Experimental Medicine, 1990
- Autoantibodies to mitochondria in systemic sclerosis. frequency and characterization using recombinant cloned autoantigenArthritis & Rheumatism, 1988